What is SS-31 (elamipretide)?
SS-31 is a tiny synthetic peptide — a chain of just four amino acids — formally named elamipretide and also known as MTP-131. The "SS" stands for Szeto-Schiller, the two researchers who first characterized this class of mitochondria-targeting peptides. The simplest way to picture it: most of your cells run on power plants called mitochondria, and SS-31 is designed to travel to those power plants and help them run more cleanly.
Inside each mitochondrion is an inner membrane rich in a special fat molecule called cardiolipin, which acts like scaffolding for the machinery that produces your cells’ energy (ATP). When that scaffolding gets damaged by oxidative stress, energy production falters. SS-31 binds to cardiolipin and helps stabilize that inner-membrane structure — research describes it partitioning into the membrane and changing its surface electrostatics, which is proposed to protect the energy machinery and reduce harmful reactive oxygen species.
That is the proposed mechanism, and it is genuinely interesting. But "interesting mechanism" and "proven, approved treatment you can dose at home" are very different things — and the rest of this page is about that gap.
Why does SS-31 target the mitochondria?
To see why a peptide would be aimed at mitochondria specifically, it helps to know what goes wrong inside them. Energy production runs along the inner mitochondrial membrane, which is folded into deep pleats called cristae that pack in the protein machinery of the electron transport chain. A signature lipid called cardiolipin holds that machinery in the right shape and helps keep the membrane sealed. Oxidative stress — a normal byproduct of burning fuel that climbs with disease and age — damages cardiolipin; the cristae flatten, electrons leak, and the mitochondrion both makes less ATP and spills more reactive oxygen species, which causes further damage in a self-reinforcing cycle.
SS-31 is built to intervene at that exact point. It is a positively charged peptide that concentrates inside mitochondria and associates with cardiolipin in the inner membrane. Laboratory work shows it partitions into the membrane interface and modulates the membrane's surface electrostatics — its local charge environment — which researchers propose as the core of how it stabilizes cristae structure, protects the energy machinery, and limits reactive-oxygen production. A 2025 review frames the downstream story as stabilized cristae, reduced oxidative stress, and improved ATP output. That is a specific, testable mechanism, and it is the reason elamipretide became the first mitochondria-targeted peptide ever approved for any disease.
It is worth being precise about what a mechanism is and is not. A well-described way a molecule could help is the starting point of drug development, not the finish line. Plenty of compounds with elegant mechanisms still fail to help patients — which is exactly what makes the human-trial record, covered next, the part that actually decides whether SS-31 works.
Has SS-31 actually been tested in people?
Yes — and this is what sets SS-31 apart from most peptides sold online. The overwhelming majority of "research peptides" have little or no controlled human data. SS-31 (elamipretide) has been through multiple registered human clinical trials, sponsored by a drug developer (Stealth BioTherapeutics) under formal regulatory oversight, across heart failure, primary mitochondrial myopathy, and Barth syndrome.
That is real, and worth respecting. But being studied is not the same as being proven, and the headline results have been mixed. In the PROGRESS-HF phase-2 trial, 71 patients with heart failure and reduced ejection fraction received placebo, 4 mg, or 40 mg of elamipretide once daily for 28 days; the drug was well tolerated but did not improve the primary measure of heart function (left-ventricular end-systolic volume) compared with placebo. In MMPOWER-3, a larger phase-3 trial, 218 people with genetically confirmed primary mitochondrial myopathy received 40 mg/day subcutaneously or placebo for 24 weeks — and the trial did not meet either of its primary endpoints (the six-minute walk test or a fatigue score), though a later post-hoc analysis suggested patients with certain nuclear-DNA mutations may have responded better.
So the honest summary is: SS-31 has been seriously tested in humans, and in two of its biggest trials it fell short of its main goals. That mixed record is exactly why it is not a casually "proven" compound.
Did any patients actually respond to SS-31?
The MMPOWER-3 myopathy trial missing its primary endpoints is the headline, but the fuller story is more interesting and more honest. When the researchers later sorted patients by the genetic cause of their disease, a prespecified subgroup stood out: people whose mitochondrial myopathy stemmed from a nuclear-DNA mutation (rather than a mutation in the mitochondria's own DNA) walked meaningfully farther on elamipretide than on placebo — about a 25-meter gain on the six-minute walk test versus essentially no change (0.3 meters) on placebo, a difference that reached statistical significance. The mitochondrial-DNA group showed no such separation from placebo.
This is genuinely worth knowing, but it has to be read carefully. A subgroup result identified after a trial has already missed its main goals is hypothesis-generating, not proof. It raises the possibility that elamipretide helps a specific genetic subset, and that possibility then has to be confirmed in a fresh, prospective trial designed around it — which is precisely the next step the developer pursued, not a conclusion you can bank today. It is also the opposite of the move that vendor pages make, which is to point at any positive number anywhere inside a failed trial and call the whole drug "proven." The accurate reading is narrower and more honest: a promising signal in one genetic subgroup, still unconfirmed, inside a trial that overall did not succeed. Until a confirmatory trial settles it, that signal is a reason for continued research, not a reason for anyone to assume the drug works for them.
Is there an approved dose of SS-31?
There is no approved consumer or general-use dose of SS-31 — and that is the most important thing on this page to get right. The numbers you see online (often "40 mg per day," or weight-based figures) are trial protocol doses, chosen by researchers for a specific study population and monitored by safety boards. They are not dosing guidance for an individual, and a trial dose for a rare disease does not translate into a "longevity" or "energy" dose for a healthy adult.
There is one narrow exception, and it is important to state it precisely. On September 19, 2025, the FDA granted accelerated approval to elamipretide — under the brand name Forzinity — as the first treatment for Barth syndrome, an ultra-rare, life-limiting genetic mitochondrial disease, in patients weighing at least 30 kg. That approval was based on an improvement in knee-extensor (leg) muscle strength, which the FDA considered reasonably likely to predict clinical benefit, and it is an accelerated approval: continued approval may depend on confirming the benefit in further trials.
Read that carefully, because the distinction is everything. Elamipretide is now an approved, prescription medicine for one specific rare disease, dispensed and dosed by specialists. It is not approved — and has no approved dose — for heart failure, longevity, athletic recovery, "anti-aging," or general mitochondrial support, which are the reasons most people search for "SS-31 dosing." For all of those uses it remains investigational.
What the evidence shows so far
Put the pieces together and a balanced picture emerges. The mechanism — cardiolipin binding, cristae stabilization, better energy efficiency — is well described in the laboratory and in preclinical models, and it earned elamipretide the distinction of being the first mitochondria-targeted peptide ever approved for any condition. That is a genuine scientific milestone.
At the same time, the human efficacy story is narrow and uneven. The one approval is for a single ultra-rare disease affecting only around 150 people in the United States, and it rests on a surrogate strength measure with confirmatory trials still owed. The larger, more general trials — in common heart failure and in mitochondrial myopathy — did not hit their primary endpoints. So the popular framing of SS-31 as a broadly proven "mitochondrial energy" or longevity peptide runs well ahead of the evidence. What we can say is supported: a real, targeted mechanism; one narrow approval; and otherwise mixed, investigational human results.
It is also worth being clear about which trial earned the approval and which did not. The Barth syndrome clearance rested on a small study in that single ultra-rare disease, using a knee-extensor muscle-strength measure as a surrogate the FDA judged reasonably likely to predict clinical benefit. It was not the larger heart-failure or general-myopathy programs — and those programs are precisely where most of the popular "energy," "recovery," and "longevity" interest actually comes from, and where the drug did not meet its goals. Holding those facts side by side is the whole point of an honest read: a genuine first-in-class mechanism and a single narrow, surrogate-based approval can both be true at the same moment that the broad, everyday benefits people search for remain unproven. Being studied, being approved for one rare condition, and being established for general use are three different things, and only the first two apply here.
| Study / model | Finding | Evidence quality |
|---|---|---|
| SS-31 biophysics, in vitro (Mitchell, JBC 2020) | Binds lipid bilayers and modulates inner-membrane surface electrostatics — the proposed core mechanism. | Laboratory mechanism (not a clinical outcome) |
| Elamipretide review (Tung, IJMS 2025) | Cardiolipin binding linked to stabilized cristae, lower oxidative stress and improved ATP output. | Preclinical / review |
| PROGRESS-HF, phase 2 (Butler, J Card Fail 2020; 71 patients) | Did NOT improve the primary measure of heart function (LVESV) vs placebo. | Randomized trial — negative |
| MMPOWER-3, phase 3 (Karaa, Neurology 2023; 218 patients, 40 mg/day SC) | Missed BOTH co-primary endpoints (6-minute walk + fatigue score). | Randomized trial — negative |
| MMPOWER-3 post-hoc (Karaa, Orphanet J Rare Dis 2024) | nDNA-mutation subgroup gained +25.2 m vs +0.3 m placebo on the 6-minute walk (p=0.03); mtDNA subgroup no benefit. | Subgroup — hypothesis-generating |
| FDA accelerated approval (Sept 2025) | Approved as Forzinity for Barth syndrome (≥30 kg) on a knee-strength surrogate, confirmatory trials still owed; not approved for any other use. | Accelerated approval — one rare disease |
Risks and the research-grade unknown
In the trials run to date, elamipretide was generally well tolerated, with injection-site reactions (redness, soreness) and occasional gastrointestinal upset among the more commonly reported effects. But "well tolerated in monitored trials" is not the same as "safe for anyone to use however they like." Long-term safety data outside the studied indications and dose ranges is limited, and the effects of unsupervised use simply have not been characterized.
There is a second, separate risk that has nothing to do with the molecule itself: the product. The only legitimate, quality-assured elamipretide is the FDA-approved prescription medicine for its one indication. Material sold online as "SS-31 research peptide" sits outside any regulated supply chain, which means its identity, purity, dose accuracy, sterility, and endotoxin levels are not verified by any oversight body. For anything injected, contamination and mislabeling are real, documented categories of risk — independent of whatever the peptide may or may not do. This is the "research-grade unknown": you often cannot be sure what is actually in the vial.
Who to ask
Because SS-31 is approved for exactly one rare disease and investigational for everything else, the only sound next step is a licensed clinician — not a forum, a vendor, or this page. If you have Barth syndrome or care for someone who does, a specialist familiar with mitochondrial disease can speak to whether the approved therapy is appropriate. If your interest is energy, longevity, or recovery, an informed physician can explain plainly that elamipretide is not approved or dose-established for those goals, and help you weigh evidence-backed alternatives against an unproven, unregulated one.
Nothing on this page is medical advice, and PeptidePanel does not sell, source, supply, endorse, or prescribe SS-31 or any compound. The purpose here is only to give you an accurate starting point for that conversation.
Tracking a clinician-directed protocol on PeptidePanel
If a licensed clinician has you on an authorized elamipretide protocol — whether the approved therapy or a supervised trial — the value of disciplined tracking is real. A clear log of doses with timestamps, relevant bloodwork and functional measures charted against reference ranges over time, and notes on any side effects gives you and your clinician a longitudinal picture that memory alone cannot.
PeptidePanel is the neutral monitoring layer for exactly that record-keeping: it logs the protocol as your clinician directs, charts the labs they ask you to follow, and flags when a dose or a lab is due. It does not decide what you take or how much — that stays entirely with you and your physician.